Pressure BioSciences, Inc. announced they are actively pursuing and evaluating multiple artificial intelligence ("AI") and machine learning ("ML") prospective partnerships. The Company expects such collaborations to accelerate the identification and prioritization of commercial product opportunities within key markets for PBIO's patented BaroFold Technology ("BaroFold??") and Ultra Shear Technology?? ("UltraShear??" or "UST??") platforms. BaroFold (14 issued patents) employs high pressure for the disaggregation and controlled refolding of proteins to their desired native structures to significantly improve the quality and production costs of protein therapeutics.

UltraShear (8 issued patents) uses intense shear forces from ultra-high pressure valve discharge to turn oil-based supplements, therapeutics, and other water-insoluble active ingredients into stable, effectively water-soluble, highly bioavailable nanoemulsions. Protein biopharmaceuticals ("biologics") are a revolutionary new class of drugs with superior specificity, target precision, lower toxicity, reduced side effects, and minimal drug-drug interaction concerns compared to traditional small molecule drugs. Unfortunately, the cost and time associated with biopharmaceutical R&D and manufacturing are significant hurdles.

A major PBIO goal in 2024 is to employ AI/ML tools to address a critical challenge - understanding protein folding kinetics to predict the optimal chemical environment for high-pressure refolding. This approach will greatly streamline biopharm pharmaceutical R&D, resulting in more efficient, efficacious, and cost-effective processes and products.